Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Vascular Medicine
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Girn, H.R.S.
Right arrow Articles by Homer-Vanniasinkam, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Girn, H.R.S.
Right arrow Articles by Homer-Vanniasinkam, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Peripheral Arterial Disease
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease

H.R.S. Girn

Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK, hrsgirn{at}aol.com

N.M. Orsi

Pathology & Tumour Biology, Leeds Institute of Molecular Medicine, St James University Hospital, Leeds, UK

S. Homer-Vanniasinkam

Leeds Vascular Institute, Leeds General Infirmary, Leeds, UK

Over the last three decades, a surge in research into the inflammatory pathophysiology of atherosclerosis has highlighted an array of cytokines and other inflammatory mediators associated with underlying inflammatory burden. The ability to identify and simultaneously measure multiple cytokines in peripheral blood highlights their potential as biomarkers of atherosclerosis. This has prompted much research in vascular medicine to identify the `at-risk' groups for atherostenotic or atheroaneurysmal disease. This review is compiled with similar intentions and aims to discern the relevant evidence for cytokine profiling in peripheral arterial disease (PAD), where such information is lacking, while providing a holistic overview of cytokine interactions in atherosclerosis. This is pertinent given that cytokine profiles from coronary artery disease and aortic aneurysm studies cannot be directly extrapolated to PAD due to differences in inflammatory environments that exist in these conditions. Whilst plaque morphology and blood rheology play an important role in the cardiac manifestations of atherosclerosis, tissue thrombogenecity is very important in PAD. Further, cytokines act in concert rather than in isolation in a disease process, and no single cytokine in a cross-sectional model is able to serve as an absolute screening marker. Thus, it is essential to understand the regulation of cytokine production in atherosclerosis prior to evaluating the viability and merits of a multimarker approach for clinical risk stratification in PAD.

Key Words: atherosclerosis • biomarkers • cytokines • interleukins • peripheral arterial disease

References

  • Stary HC, Chandler AB, Glagov S. et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462—78.[Abstract/Free Full Text]
  • Selvin E., Erlinger TP Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999—2000. Circulation 2004; 110: 738—43.[Abstract/Free Full Text]
  • Hirsch AT, Criqui MH, Treat-Jacobson D. et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317—24.[Abstract/Free Full Text]
  • Dormandy JA, Rutherford RB Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic Intersociety consensus (TASC). J Vasc Surg 2000; 31: 1—296.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Schonbeck U., Sukhova GK, Gerdes N., Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 2002; 161: 499—506.[Abstract/Free Full Text]
  • Hashmi S., Zeng QT Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006; 17: 699—706.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dinarello CA Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253—65.[CrossRef][Medline] [Order article via Infotrieve]
  • Libby P., Sukhova G., Lee RT, Galis ZS Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25(suppl 2): S9—12.
  • Bresnihan B., Alvaro-Gracia JM, Cobby M. et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196—204.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Fiotti N., Giansante C., Ponte E. et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999; 145: 51—60.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McDermott MM, Guralnik JM, Corsi A. et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 2005; 150: 276—81.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Zheng H., Fletcher D., Kozak W. et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995; 3: 9—19.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Dinarello CA IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103(1 Pt 1): 11—24.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Tzoulaki I., Murray GD, Lee AJ, Rumley A., Lowe GD, Fowkes FG C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976—83.[Abstract/Free Full Text]
  • Oyama J., Shimokawa H., Morita S., Yasui H., Takeshita A. Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. Coron Artery Dis 2001; 12: 567—71.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Whitman SC, Ravisankar P., Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(—/—) mice through release of interferon-gamma. Circ Res 2002; 90: E34—38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mallat Z., Corbaz A., Scoazec A. et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41—45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Elhage R., Jawien J., Rudling M. et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003; 59: 234—40.[Abstract/Free Full Text]
  • Mallat Z., Corbaz A., Scoazec A. et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598—603.[Abstract/Free Full Text]
  • Tiret L., Godefroy T., Lubos E. et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005; 112: 643—50.[Abstract/Free Full Text]
  • Gilardini L., McTernan PG, Girola A. et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006; 189: 401—407.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindholt JS, Shi GP Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453—63.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Wan YY, Flavell RA The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 2006; 212: 114—30.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Vadiveloo PK, Stanton HR, Cochran FW, Hamilton JA Interleukin-4 inhibits human smooth muscle cell proliferation. Artery 1994; 21: 161—81.[Web of Science][Medline] [Order article via Infotrieve]
  • Khew-Goodall Y., Wadham C., Stein BN, Gamble JR, Vadas MA Stat6 activation is essential for interleukin-4 induction of P-selectin transcription in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1421—29.[Abstract/Free Full Text]
  • Shimizu K., Libby P., Mitchell RN Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc Med 2005; 15: 142—48.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Morita Y., Gupta R., Seidl KM, McDonagh KT, Fox DA Cytokine production by dendritic cells genetically engineered to express IL-4: induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. J Gene Med 2005; 7: 869—77.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Szodoray P., Timar O., Veres K. et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines — immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006; 64: 336—44.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ishibashi T., Yokoyama K., Shindo J. et al. Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor. Arterioscler Thromb 1994; 14: 1534—41.[Abstract/Free Full Text]
  • Shindo J., Ishibashi T., Yokoyama K. et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. Circulation 1999; 99: 2150—56.[Abstract/Free Full Text]
  • Hamilton JA, Stanley ER, Burgess AW, Shadduck RK Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J Cell Physiol 1980; 103: 435—45.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hamilton JA, Anderson GP GM-CSF biology. Growth Factors 2004; 22: 225—31.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cosio BG, Mann B., Ito K., Jazrawi E., Barnes PJ, Chung KF, Adcock IM Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am J Respir Crit Care Med 2004; 170: 141—47.[Abstract/Free Full Text]
  • Seiler C., Pohl T., Wustmann K. et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012—17.[Abstract/Free Full Text]
  • Van Royen N., Schirmer SH, Atasever B. et al. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112: 1040—46.[Abstract/Free Full Text]
  • Grundmann S., Hoefer I., Ulusans S. et al. Granulocyte-macrophage colony-stimulating factor stimulates arteriogenesis in a pig model of peripheral artery disease using clinically applicable infusion pumps. J Vasc Surg 2006; 43: 1263—69.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Namen AE, Lupton S., Hjerrild K. et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333: 571—73.[CrossRef][Medline] [Order article via Infotrieve]
  • Jiang Q., Li WQ, Aiello FB et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005; 16: 513—33.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Damas JK, Waehre T., Yndestad A. et al. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 2003; 107: 2670—76.[Abstract/Free Full Text]
  • Prunet C., Montange T., Vejux A. et al. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry A 2006; 69: 359—73.[Medline] [Order article via Infotrieve]
  • Nylaende M., Kroese A., Stranden E. et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11: 21—28.[Abstract/Free Full Text]
  • DePalma RG, Hayes VW, May PE et al. Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional study. Vascular 2006; 14: 193—200.[CrossRef][Medline] [Order article via Infotrieve]
  • Armitage JD, Lindsey NJ, Homer-Vanniasinkam S. The role of endothelial cell reactive antibodies in peripheral arterial disease. Eur J Vasc Endovasc Surg 2006; 31: 170—75.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Libra M., Signorelli SS, Bevelacqua Y. et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006; 59: 211—15.[Abstract/Free Full Text]
  • Allison MA, Criqui MH, McClelland RL et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190—97.[Abstract/Free Full Text]
  • Hoogeveen RC, Morrison A., Boerwinkle E. et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301—307.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Danielsson P., Truedsson L., Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 2005; 10: 191—98.[Abstract/Free Full Text]
  • Ziegler S., Kudlacek S., Luger A., Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005; 182: 175—80.[Web of Science][Medline] [Order article via Infotrieve]
  • DePalma RG, Hayes VW, Cafferata HT et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 2003; 111: 215—21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Silvestro A., Scopacasa F., Ruocco A. et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 2003; 8: 225—32.[Abstract/Free Full Text]
  • Testa M., De Ruvo E., Russo A. et al. Induction of interleukin-1beta and interleukin-6 gene expression in hypoperfused skeletal muscle of patients with peripheral arterial disease. Ital Heart J 2000; 1: 64—67.[Medline] [Order article via Infotrieve]
  • Kirk G., Hickman P., McLaren M., Stonebridge PA, Belch JJ Interleukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur J Vasc Endovasc Surg 1999; 18: 434—38.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Haddy N., Sass C., Droesch S. et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277—83.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Von der Thusen JH, Kuiper J., van Berkel TJ, Biessen EA Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003; 55: 133—66.[Abstract/Free Full Text]
  • Klouche M., Rose-JohnS., SchmiedtW., BhakdiS. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000; 101: 1799—805.[Abstract/Free Full Text]
  • Hauer AD, Uyttenhove C., de Vos P. et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005; 112: 1054—62.[Abstract/Free Full Text]
  • Uyemura K., Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130—38.[Web of Science][Medline] [Order article via Infotrieve]
  • Zhang X., Niessner A., Nakajima T. et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006; 98: 524—31.[Abstract/Free Full Text]
  • Baidya SG, Zeng QT, Wang X., Guo HP T helper cell related interleukins and the angiographic morphology in unstable angina. Cytokine 2005; 30: 303—10.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Steppich BA, Moog P., Matissek C. et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007; 190: 443—51.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hochrein H., O'Keeffe M., Luft T. et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000; 192: 823—33.[Abstract/Free Full Text]
  • Chung HK, Lee IK, Kang H. et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002; 34: 451—61.[Web of Science][Medline] [Order article via Infotrieve]
  • Tedgui A., Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515—81.[Abstract/Free Full Text]
  • Buono C., Come CE, Stavrakis G., Maguire GF, Connelly PW, Lichtman AH Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003; 23: 454—60.[Abstract/Free Full Text]
  • Xiong W., Zhao Y., Prall A., Greiner TC, Baxter BT Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a murine model. J Immunol 2004; 172: 2607—12.[Abstract/Free Full Text]
  • Leon ML, Zuckerman SH Gamma interferon: a central mediator in atherosclerosis. Inflamm Res. 2005; 54: 395—411.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Young JL, Libby P., Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554—67.[Web of Science][Medline] [Order article via Infotrieve]
  • Harvey EJ, Ramji DP Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res 2005; 67: 11—20.[Abstract/Free Full Text]
  • Barath P., Fishbein MC, Cao J., Berenson J., Helfant RH, Forrester JS Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297—302.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Galis ZS, Muszynski M., Sukhova GK, Simon-Morrissey E., Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501—507.[Web of Science][Medline] [Order article via Infotrieve]
  • Taubman MB, Fallon JT, Schecter AD et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997; 78: 200—204.[Web of Science][Medline] [Order article via Infotrieve]
  • Chung ES, Packer M., Lo KH, Fasanmade AA, Willerson JT Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133—40.[Abstract/Free Full Text]
  • Muller-Ehmsen J., Schwinger RH TNF and congestive heart failure: therapeutic possibilities. Expert opinion on therapeutic targets. 2004; 8: 203—209.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Boisvert WA Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004; 14: 161—65.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Shin WS, Szuba A., Rockson SG The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002; 160: 91—102.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005; 6: 21—29.[Medline] [Order article via Infotrieve]
  • Leu HB, Wu CC, Wu TC, Lin SJ, Chen JW Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia. J Formos Med Assoc 2004; 103: 914—20.[Web of Science][Medline] [Order article via Infotrieve]
  • Charo IF, Taubman MB Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858—66.[Abstract/Free Full Text]
  • Ito T., Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets 2003; 2: 257—65.[CrossRef]
  • Boisvert WA, Santiago R., Curtiss LK, Terkeltaub RA A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353—63.[Web of Science][Medline] [Order article via Infotrieve]
  • Yamagishi M., Higashikata T., Ishibashi-Ueda H. et al. Sustained upregulation of inflammatory chemokine and its receptor in aneurysmal and occlusive atherosclerotic disease: results from tissue analysis with cDNA macroarray and real-time reverse transcriptional polymerase chain reaction methods. Circ J 2005; 69: 1490—95.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Moreau M., Brocheriou I., Petit L., Ninio E., Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999; 99: 420—26.[Abstract/Free Full Text]
  • Martins TB, Anderson JL, Muhlestein JB et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol 2006; 125: 906—13.[Abstract/Free Full Text]
  • Mallat Z., Besnard S., Duriez M. et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17—24.[Web of Science][Medline] [Order article via Infotrieve]
  • Namiki M., Kawashima S., Yamashita T. et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21—29.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Mallat Z., Heymes C., Ohan J., Faggin E., Leseche G., Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611—16.[Abstract/Free Full Text]
  • Terkeltaub RA IL-10: An `immunologic scalpel' for atherosclerosis? Arterioscler Thromb Vasc Biol 1999; 19: 2823—25.[Free Full Text]
  • Pinderski Oslund LJ, Hedrick CC, Olvera T. et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847—53.[Abstract/Free Full Text]
  • Poe JC, Wagner DH Jr, Miller RW, Stout RD, Suttles J. IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. J Immunol 1997; 159: 846—52.[Abstract]
  • Anguera I., Miranda-Guardiola F., Bosch X. et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002; 144: 811—17.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Smith DA, Irving SD, Sheldon J., Cole D., Kaski JC Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746—49.[Abstract/Free Full Text]
  • Heeschen C., Dimmeler S., Hamm CW et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109—14.[Abstract/Free Full Text]
  • Davis VA, Persidskaia RN, Baca-Regen LM, Fiotti N., Halloran BG, Baxter BT Cytokine pattern in aneurysmal and occlusive disease of the aorta. J Surg Res 2001; 101: 152—56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Metcalfe JC, Grainger DJ Transforming growth factor-beta and the protection from cardiovascular injury hypothesis. Biochem Soc Trans 1995; 23: 403—406.[Web of Science][Medline] [Order article via Infotrieve]
  • Grainger DJ Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399—404.[Abstract/Free Full Text]
  • Yamagami S., Yokoo S., Mimura T., Amano S. Effects of TGFbeta2 on immune response-related gene expression profiles in the human corneal endothelium. Invest Ophthalmol Vis Sci 2004; 45: 515—21.[Abstract/Free Full Text]
  • Ashcroft GS Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect 1999; 1: 1275—82.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Turner M., Chantry D., Feldmann M. Transforming growth factor beta induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine 1990; 2: 211—16.[CrossRef][Medline] [Order article via Infotrieve]
  • Kulkarni AB, Huh CG, Becker D. et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90: 770—74.[Abstract/Free Full Text]
  • Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 2000; 113(Pt 13): 2355—61.[Abstract]
  • Mallat Z., GojovaA., Marchiol-Fournigault C. et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89: 930—34.[Abstract/Free Full Text]
  • Lutgens E., Gijbels M., Smook M. et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975—82.[Abstract/Free Full Text]
  • Erren M., Reinecke H., Junker R. et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355—63.[Abstract/Free Full Text]

Vascular Medicine, Vol. 12, No. 4, 299-309 (2007)
DOI: 10.1177/1358863X07083387
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Girn, H.R.S.
Right arrow Articles by Homer-Vanniasinkam, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Girn, H.R.S.
Right arrow Articles by Homer-Vanniasinkam, S.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Peripheral Arterial Disease
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?